<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254240</url>
  </required_header>
  <id_info>
    <org_study_id>DER-USZ-AAN-005</org_study_id>
    <nct_id>NCT01254240</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases</brief_title>
  <acronym>PRUVAB</acronym>
  <official_title>Randomized Double-blind Phase 2 Study of Impact of Ultraviolet A (UVA) on Pruritus During Ultraviolet A/B (UVA/B) Phototherapy of Inflammatory Dermatoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind prospective randomized monocenter study comparing the efficacy of two&#xD;
      phototherapy ultraviolet spectra on pruritus (itching) of inflammatory skin diseases. 40&#xD;
      patients per treatment, in total 80 study participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with a skin disease and the given indication for a phototherapy with Ultraviolet&#xD;
      B narrow-band (UVB narrowband, 311nm) with or without Ultraviolet A (UVA, 320-400 nm), the&#xD;
      subjective pruritus levels and clinical severity will be measured before, during and after&#xD;
      completion of the 16-week therapy (40 patients per group). Patients will be recruited in the&#xD;
      department of dermatology of the University Hospital ZÃ¼rich in the outpatient clinic.&#xD;
      Following oral and written consent, pruritus levels will be measured by a visual analogue&#xD;
      scale and a new, detailed pruritus score 2 before start of therapy, every 4 weeks after start&#xD;
      as well as after completion of the phototherapy. Phototherapy is to be administered 3 times&#xD;
      per week. The study includes 5 study visits and up to 43 treatment visits that include&#xD;
      administration of phototherapy only.&#xD;
&#xD;
      A physical examination including clinical scores (Psoriasis Area and Severity Index PASI,&#xD;
      Eczema Area and Severity Index EASI, Physician's static global assessment PSGA and&#xD;
      Dermatology Dynamics Vector DDV) will be performed at every visit. During the first physical&#xD;
      examination the Fitzpatrick-skin type of patient will be recorded, the demographics, the Body&#xD;
      Mass Index (BMI), diagnosis, past medical history, co-morbidities, concomitant medication and&#xD;
      the number of past UVA/B treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-D Pruritus score and VAS Score at 16 weeks</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Eczema</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>UVA/B phototherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UVA/B phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UVB phototherapy treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UVB phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UVA / UVB phototherapy</intervention_name>
    <description>UVA / UVB phototherapy</description>
    <arm_group_label>UVA/B phototherapy treatment</arm_group_label>
    <other_name>Waldmann phototherapy cabins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UVB phototherapy</intervention_name>
    <description>UVB phototherapy</description>
    <arm_group_label>UVB phototherapy treatment</arm_group_label>
    <other_name>Waldmann phototherapy cabins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Pruritic inflammatory diseases such as atopic dermatitis, other types of eczema,&#xD;
        psoriasis, prurigo simplex subacuta and others.&#xD;
&#xD;
        Main inclusion criteria:&#xD;
&#xD;
          -  Pruritus VAS Score 5 or higher at screening.&#xD;
&#xD;
          -  Dermatological indication for a phototherapy with UVB nb / UVA&#xD;
&#xD;
          -  Oral and written informed patient consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Patients will be excluded from the study if they fulfill any of the following criteria:&#xD;
&#xD;
          1. Foreseeable interruption of the light therapy for more than 14 days, or interruption&#xD;
             of the light therapy for more than 14 days during the study&#xD;
&#xD;
          2. Heightened photosensitivity for UVA or UVB&#xD;
&#xD;
          3. Withdrawal of consent to participate&#xD;
&#xD;
          4. Concomitant participation in another study or having taken part in another clinical&#xD;
             study within the last 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenther Hofbauer, MD, Leading Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Department of Dermatology</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

